Supplementary prospectus and amended timetable
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Later from Actinogen Medical
- R&D Rebate
- Appendix 4D & Half Year Report
- Launch of XanADu Phase II Clinical Trial
- US FDA Feedback Enhances Alzheimers Study
- US Patent Granted-Further Extends Xanamem Protection
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical